Shield Therapeutics PLC (LON:STX) had its price target increased by equities researchers at Canaccord Genuity from GBX 235 ($3.07) to GBX 241 ($3.15) in a research report issued on Tuesday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 54.49% from the company’s previous close.

Separately, Liberum Capital reaffirmed a “buy” rating and set a GBX 310 ($4.05) price objective on shares of Shield Therapeutics PLC in a research note on Tuesday.

Shield Therapeutics PLC (LON:STX) opened at 160.00 on Tuesday. The company’s market cap is GBX 173.02 billion. Shield Therapeutics PLC has a 1-year low of GBX 147.00 and a 1-year high of GBX 190.00. The stock’s 50 day moving average is GBX 156.35 and its 200 day moving average is GBX 166.01.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.